Overview

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

Status:
Withdrawn

Trial end date:
2019-10-28

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals